Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialGeorge D. Demetri, Paolo G. Casali, Piotr Rutkowski et al.|The Lancet|2012Cited by 1.4k
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN StudyEric Van Cutsem, Alberto Zaniboni, Erika Martinelli et al.|The Oncologist|2018Cited by 143